The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AGN-PC-00HO7L     (17-ethanoyl-6,10,13- trimethyl-3-oxo-2,8,9...

Synonyms: SureCN5021332, AC1L1HAP, AR-1H2191, AC1Q6OH3, LT00244865, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MEGESTROL ACETATE

  • Significant and persistent weight gain associated with MA administration was the most notable difference in tolerability between the two agents [1].
  • CONCLUSION: In geriatric weight-loss patients with cachexia, certain cytokines and nutritional indicators were effective in predicting long-term mortality, regardless of treatment with MA [2].
  • In patients with or without visceral metastases, second-line treatment with anastrozole resulted in a CB rate of 31.4 and 51.8%, respectively, compared with 31.9 and 47.1%, respectively, for those treated with MA [3].
  • The two most widely used synthetic progestins in breast cancer treatment, medroxyprogesterone acetate (MPA) and megestrol acetate (MA), are reviewed with regard to pharmacological, endocrinological and clinical aspects [4].
  • The use of MA 480 mg/day during RT was effective in reversing anorexia and weight loss in spite of the acute RT effects, and helped most patients to well tolerate specific tumor therapy [5].

High impact information on MEGESTROL ACETATE

  • Response to MPA or MA is probably independent of the presence of progesterone receptor [6].
  • The new non-steroidal and steroidal aromatase inhibitors are at least as effective as megestrol acetate (MA) as second-line hormonal agents in postmenopausal women with breast cancer [7].
  • A stepwise decrease in androgen receptors (AR) was observed, indicating that the two progestins (MPA and MA) may also act through AR, and/or interfere with the replenishment of AR [8].

Biological context of MEGESTROL ACETATE

  • Cells treated with MA or P showed less glandular organization but expressed ER with PR downregulation [9].

Analytical, diagnostic and therapeutic context of MEGESTROL ACETATE

  • Previous exposure to chemotherapy does not appear to jeopardize chances for response to MA [6].


  1. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Goss, P.E. Breast Cancer Res. Treat. (1998) [Pubmed]
  2. Risk factors relating blood markers of inflammation and nutritional status to survival in cachectic geriatric patients in a randomized clinical trial. Yeh, S.S., Hafner, A., Chang, C.K., Levine, D.M., Parker, T.S., Schuster, M.W. Journal of the American Geriatrics Society. (2004) [Pubmed]
  3. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Howell, A., Robertson, J.F., Vergote, I. Breast Cancer Res. Treat. (2003) [Pubmed]
  4. Progestins in breast cancer treatment. A review. Lundgren, S. Acta oncologica (Stockholm, Sweden) (1992) [Pubmed]
  5. Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy. Erkurt, E., Erkisi, M., Tunali, C. J. Exp. Clin. Cancer Res. (2000) [Pubmed]
  6. The role of progestins in the treatment of breast cancer. Blumenschein, G.R. Semin. Oncol. (1983) [Pubmed]
  7. Aromatase inhibitors. Cunnick, G.H., Mokbel, K. Current medical research and opinion. (2001) [Pubmed]
  8. The influence of progestins on receptor levels in breast cancer metastasis. Lundgren, S., Kvinnsland, S., Varhaug, J.E., Utaaker, E. Anticancer Res. (1987) [Pubmed]
  9. Hormonal modulation of Ishikawa cells during three-dimensional growth in vitro. Pinelli, D.M., Drake, J., Williams, M.C., Cavanagh, D., Becker, J.L. J. Soc. Gynecol. Investig. (1998) [Pubmed]
WikiGenes - Universities